Pulmonx (LUNG) Cost of Revenue (2019 - 2025)

Pulmonx (LUNG) has 7 years of Cost of Revenue data on file, last reported at $5.4 million in Q3 2025.

• On a quarterly basis, Cost of Revenue rose 1.66% year-over-year to $5.4 million in Q3 2025; TTM through Sep 2025 was $24.5 million, a 19.45% increase from a year earlier, with the FY2024 full-year figure at $21.8 million, up 21.56% from the prior year.
• Cost of Revenue for Q3 2025 stood at $5.4 million, down from $6.7 million in the prior quarter.
• Over the last five years, Cost of Revenue for LUNG reached as high as $6.7 million in Q2 2025 and fell as low as $500000.0 in Q4 2022.
• Historically, Cost of Revenue has averaged $4.3 million across 5 years, with a median of $4.5 million in 2023.
• Across the five-year window, Cost of Revenue slumped 85.54% in 2022 and surged 875.6% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $3.5 million in 2021, then sank by 85.54% to $500000.0 in 2022, then jumped by 875.6% to $4.9 million in 2023, then climbed by 26.59% to $6.2 million in 2024, then fell by 11.74% to $5.4 million in 2025.
• Per Business Quant data, the three most recent Cost of Revenue figures were $5.4 million in Q3 2025, $6.7 million in Q2 2025, and $6.2 million in Q1 2025.